Evidence map›Paper›PMID 36354581›Full record

ArticleBioengineering (Basel, Switzerland)2022

Functional Expression of the Recombinant Spike Receptor Binding Domain of SARS-CoV-2 Omicron in the Periplasm of

Woo Sung Kim, Ji Hyun Kim, Jisun Lee, Su Yeon Ka, Hee Do Chae, Inji Jung, Sang Taek Jung, Jung-Hyun Na

Open access · goldAbstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Woo Sung KimDepartment of Pharmaceutical Engineering, Sangji University, Wonju 26339, Korea.
Ji Hyun KimDepartment of Pharmaceutical Engineering, Sangji University, Wonju 26339, Korea.
Jisun LeeDepartment of Biomedical Sciences, Graduate School, Korea University, Seoul 02841, Korea.
Su Yeon KaDepartment of Pharmaceutical Engineering, Sangji University, Wonju 26339, Korea.
Hee Do ChaeDepartment of Pharmaceutical Engineering, Sangji University, Wonju 26339, Korea.
Inji JungDepartment of Biomedical Sciences, Graduate School, Korea University, Seoul 02841, Korea.
Sang Taek JungDepartment of Biomedical Sciences, Graduate School, Korea University, Seoul 02841, Korea.ORCID 0000-0001-7217-979X
Jung-Hyun NaDepartment of Pharmaceutical Engineering, Sangji University, Wonju 26339, Korea.ORCID 0000-0002-5257-2428
Sangji University · KRKorea University · KR

Funding

National Research Foundation of Korea NRF-2021R1F1A1060240, 2021M3H9A1097596
6 · The paper itself

Abstract

A new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant known as Omicron has caused a rapid increase in recent global patients with coronavirus infectious disease 2019 (COVID-19). To overcome the COVID-19 Omicron variant, production of a recombinant spike receptor binding domain (RBD) is vital for developing a subunit vaccine or a neutralizing antibody. Although bacterial expression has many advantages in the production of recombinant proteins, the spike RBD expressed in a bacterial system experiences a folding problem related to disulfide bond formation. In this study, the soluble Omicron RBD was obtained by a disulfide isomerase-assisted periplasmic expression system in

Indexed as

E. colifunctional expressionomicronspike receptor binding domain

Identifiers

PMID36354581
PMCPMC9687980
OpenAlexW4308766205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.